Related Experiment Video
Updated: Jun 30, 2026
05:58
Dissociation of Human and Mouse Tumor Tissue Samples for Single-cell RNA Sequencing
Published on: August 16, 2024
Unveiling tumor heterogeneity by single cell RNA-sequencing: From basic considerations to clinical applications.
Tina Fuchs1, Michael Menzel1, Katharina Mößinger2
1Institute of Pathology, Heidelberg University Hospital, Center for Personalized Medicine (ZPM), German Cancer Consortium (DKTK), Translational Lung Research Center (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
Seminars in Cancer Biology
|June 28, 2026
Summary
Single-cell RNA sequencing (scRNA-seq) reveals tumor complexity and aids cancer therapy. This technology is increasingly vital in clinical trials for personalized medicine, despite ongoing challenges.
Area of Science:
- Oncology
- Genomics
- Immunology
Background:
- Tumor heterogeneity presents a major challenge in cancer treatment.
- Single-cell RNA sequencing (scRNA-seq) offers high-resolution insights into cellular complexity.
Purpose of the Study:
- To review the technical aspects and evolution of scRNA-seq.
- To highlight scRNA-seq applications in understanding tumor biology and treatment resistance.
- To assess the integration of scRNA-seq in clinical trials for precision medicine.
Main Methods:
- Review of scRNA-seq technologies and computational pipelines.
- Analysis of scRNA-seq applications in lung cancer research.
- Survey of clinical trials incorporating scRNA-seq endpoints.
Main Results:
- scRNA-seq elucidates tumor architecture, immune microenvironment, and resistance mechanisms.
- Machine learning integration accelerates biomarker discovery and risk stratification.
- Approximately 380 trials utilize scRNA-seq, demonstrating its growing importance.
Conclusions:
- scRNA-seq provides crucial cellular and molecular data complementing traditional endpoints.
- Technological advancements are expanding scRNA-seq's role in precision medicine.
- Challenges in cost, scalability, and validation need addressing for clinical deployment.
